duraphat tannpasta 5 mg/g
colgate palmolive a/s - sodium fluoride - tannpasta - 5 mg/g
hydroxyzine medical valley filmuhúðuð tafla 25 mg
medical valley invest ab - hydroxyzinum hýdróklóríð - filmuhúðuð tafla - 25 mg
imodium filmuhúðuð tafla 2 mg
mcneil sweden ab - loperamidum hýdróklóríð - filmuhúðuð tafla - 2 mg
ketogan endaþarmsstíll 10 mg + 50 mg
pfizer aps - n.n-dimethyl-4.4-diphenyl-3-butene-2-amine klóríð; cetobemidonum hýdróklóríð - endaþarmsstíll - 10 mg + 50 mg
magnesia medic filmuhúðuð tafla 500 mg
viatris aps - magnesii hydroxidum - filmuhúðuð tafla - 500 mg
toilax sýruþolin tafla og endaþarmsdreifa
orion corporation - bisacodylum inn - sýruþolin tafla og endaþarmsdreifa
toilax endaþarmsdreifa 2 mg/ml
orion corporation - bisacodylum inn - endaþarmsdreifa - 2 mg/ml
toilax magasýruþolin tafla 5 mg
orion corporation - bisacodylum inn - magasýruþolin tafla - 5 mg
xtandi
astellas pharma europe b.v. - enzalutamíð - blöðruhálskirtli - innkirtla meðferð - xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (see section 5. the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (crpc) (see section 5. the treatment of adult men with metastatic crpc who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. the treatment of adult men with metastatic crpc whose disease has progressed on or after docetaxel therapy.
losartan medical valley filmuhúðuð tafla 12,5 mg
medical valley invest ab - losartanum kalíum - filmuhúðuð tafla - 12,5 mg